Trillium Therapeutics Inc.
TRIL
TRIL was delisted on the 16th of November, 2021.
131 hedge funds and large institutions have $1.12B invested in Trillium Therapeutics Inc. in 2020 Q4 according to their latest regulatory filings, with 40 funds opening new positions, 57 increasing their positions, 28 reducing their positions, and 22 closing their positions.
104% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 28
82% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 22
17% more capital invested
Capital invested by funds: $958M → $1.12B (+$161M)
17% more funds holding in top 10
Funds holding in top 10: 6 → 7 (+1)
15% more funds holding
Funds holding: 114 → 131 (+17)
15% less call options, than puts
Call options by funds: $23.6M | Put options by funds: $27.9M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$24.6M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$22.8M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$20.8M |
| 4 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$14.8M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$10.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VA
VR Adviser
New York
|
-$45.6M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$35.5M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$12.6M |
| 4 |
MWNA
Marshall Wace North America
New York
|
-$7.86M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$7.6M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
151
Bank Julius Baer & Co
Zurich,
Switzerland
| – | -$6K | -450 | Closed |
|
152
Simplex Trading
Chicago,
Illinois
| – | +$411K | +28,499 | +124% |
|
TRIL Hedge Fund Activity: Q4 2020 in Review
131 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Trillium Therapeutics Inc. (TRIL) for Q4 2020, worth a combined $1.12B — up 17% from $958M a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new TRIL positions and 22 closed out — a net gain of 18 holders — while 57 added to existing stakes and 28 trimmed.
The largest buyer was OrbiMed, adding an estimated $24.6M. The largest seller was VR Adviser, cutting an estimated $45.6M.
- 131 institutional investors held Trillium Therapeutics Inc. (TRIL) as of Q4 2020, up from 114 in Q3 2020.
- Funds reported $1.12B of Trillium Therapeutics Inc. stock for Q4 2020, up 17% quarter-over-quarter.
- 40 funds opened new Trillium Therapeutics Inc. positions in Q4 2020 and 22 closed out, a net change of +18 holders.
- The largest Trillium Therapeutics Inc. buyer in Q4 2020 was OrbiMed, an estimated $24.6M added.
- The largest Trillium Therapeutics Inc. seller in Q4 2020 was VR Adviser, an estimated $45.6M sold.
Based on aggregated 13F filings for Q4 2020.